I would like to thank posters for the thoughtful contribution to this thread and information and insights to shareholders. I would like to add a couple of points. I was at a presentation by Mitchell Glass a little while ago. He listed about eight indications for CPn10 including Psiorasis and ended by saying "and we haven't given up on RA either" Shareholders should realise that funds are in short supply and the Company has to select the best bets carefully. Given the spectacular results of a trial of CPn10 in Lupus in a mouse model, I am sure that they have chosen the right indication. This says nothing about the other possible indications in the auto immune area. The paper on DAMP, RAMPS and PAMPS by Guy's hospital in London indicates that CPn 10 should be useful in the whole range of auto immune diseases.
IVX Price at posting:
8.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)